Lineage Cell Therapeutics Achieves $5 Million Milestone Payment Under Roche Agreement
I'm PortAI, I can summarize articles.
Lineage Cell Therapeutics Inc. has achieved a $5 million milestone payment under its collaboration with Genentech and Roche for the OpRegen cell therapy program. This payment, based on manufacturing and clinical advancements, will be received within 30 days. Portions of the payment will be allocated to the Israel Innovation Authority and Hadasit Medical Research, as per existing agreements. OpRegen is in a Phase 2a trial for treating geographic atrophy due to age-related macular degeneration.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments